Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial

The optimal way to use immunomodulatory drugs as components of induction and maintenance therapy for multiple myeloma is unresolved. We addressed this question in a large phase III randomized trial, Myeloma XI. Patients with newly diagnosed multiple myeloma (n=2,042) were randomized to induction the...

Descripción completa

Detalles Bibliográficos
Autores principales: Jackson, Graham H., Davies, Faith E., Pawlyn, Charlotte, Cairns, David A., Striha, Alina, Collett, Corinne, Waterhouse, Anna, Jones, John R., Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D., Karunanithi, Kamaraj, Lindsay, Jindriska, Allotey, David, Shafeek, Salim, Jenner, Matthew W., Cook, Gordon, Russell, Nigel H., Kaiser, Martin F., Drayson, Mark T., Owen, Roger G., Gregory, Walter M., Morgan, Gareth J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252959/
https://www.ncbi.nlm.nih.gov/pubmed/32499244
http://dx.doi.org/10.3324/haematol.2020.247130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252959/
https://www.ncbi.nlm.nih.gov/pubmed/32499244
http://dx.doi.org/10.3324/haematol.2020.247130

Ejemplares similares